Elizaveta Novokhatskaya

Dr. Elizaveta Novokhatskaya

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Anastasia BlokhinaAnastasia Blokhina
Anastasia Blokhina
AEAlexandra Ershova
Alexandra Ershova
AKAnna Kiseleva
Anna Kiseleva
ESEvgeniia Sotnikova
Evgeniia Sotnikova
MZMarija Zaicenoka
Marija Zaicenoka
ODOxana M. Drapkina
Oxana M. Drapkina
Familial dysbetalipoproteinemia (FD) is a prevalent and highly atherogenic hyperlipoproteinemia associated with the ε2/ε2 APOE genotype or rare APOE variants. The contributions of additional genetic and clinical factors to the FD phenotype remain unclear. We investigated these factors in both autosomal recessive and autosomal dominant forms of FD. Targeted (n = 4666) and exome (n = 194) sequencing were used to identify the ε2/ε2 APOE genotype or rare FD-causative APOE variants. Twenty-four lipid-related genes and forty variants included in a polygenic risk score for hypertriglyceridemia (HTG) were analyzed. FD was defined by the presence of FD variants and triglycerides (TG) ≥ 1.5 mmol/L (main study group). The comparison group consisted of patients with FD variants but TG < 1.5 mmol/L. Univariable and multivariable regression analyses were performed. A total of 71 unrelated subjects were identified (45.1% male, median age 50 years). FD was diagnosed in 52 patients, while 19 had FD variants only. Age (p = 0.019), elevated polygenic risk for HTG (p = 0.001), and the presence of metabolic syndrome components (p = 0.014) were independently associated with the FD phenotype. TG levels were significantly associated with polygenic burden (0.05 mmol/L per percentile), the presence of additional rare lipid-related variants (7.0 mmol/L), and glucose metabolism disorders (3.62 mmol/L), together explaining 30% of TG variance in cross-validated model. These results highlight the interplay of genetic and metabolic factors in FD development and support the integration of HTG genetic risk scores and metabolic control into personalized FD management.

Verified
Journal Article
Open access
PDF file
Anastasia BlokhinaAnastasia Blokhina
Anastasia Blokhina
Alexey MeshkovAlexey Meshkov
Alexey Meshkov
AEAlexandra Ershova
Alexandra Ershova
MZMarija Zaicenoka
Marija Zaicenoka
VMViktoriya Mikhailina
Viktoriya Mikhailina
ODOxana M. Drapkina
Oxana M. Drapkina
Severe hypertriglyceridemia (HTG) is genetically heterogeneous, but its genetic architecture remains incompletely characterized. We investigated the genetic determinants of severe HTG in 123 patients with triglyceride (TG) levels > 5.0 mmol/L and available NGS data. We analyzed rare variants in LPL, APOC2, APOA5, GPIHBP1, LMF1, and APOE; the ε2/ε2 APOE genotype; and TG-polygenic risk score (PRS) based on 40 variants. Major genetic determinants were identified in 65.0% of individuals, including rare variants in chylomicronemia genes (24.4%; 28 variants, including 10 novel, 53.6% in LPL), rare APOE variants or the ε2/ε2 genotype (18.7%, overlapping with chylomicronemia variants in 4.1%), and an extreme polygenic burden (35.8%; PRS > 90th percentile), including 26.0% with isolated polygenic HTG. The remaining 35.0% had moderate-to-low PRS. The cohort was categorized into familial chylomicronemia syndrome (FCS, n = 7), multifactorial chylomicronemia syndrome (MCS, n = 21), polygenic HTG (n = 32), familial dysbetalipoproteinemia (FD, n = 20), and moderate-to-low PRS (n = 43) groups based on genetic determinants. FCS had the lowest PRS percentile (median 26) and the most distinct clinical profile, with the highest TG levels (median 30.60 mmol/L) and 6–24-fold higher odds of pancreatitis compared with other groups (p < 0.05), alongside a lower body mass index (median 23.0 kg/m2) than all groups except MCS, whereas FD had the lowest TG levels (10.20 mmol/L, p < 0.05). These results further advance the understanding of the complex genetic architecture of severe HTG and demonstrate that broader genetic analysis, including APOE and TG-PRS, may increase the yield of genetic determinants in severe HTG.

29 April 2026 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
AKA. A. Kucherov
A. A. Kucherov
AEAlexandra Ershova
Alexandra Ershova
ENElizaveta Novokhatskaya
Elizaveta Novokhatskaya
VSV. E. Syutkin
V. E. Syutkin
ODOxana M. Drapkina
Oxana M. Drapkina
Aim.  To characterize the cardiometabolic profile, intake rate and effectiveness of lipid-lowering therapy (LLT) in liver transplant recipients. Material and methods.  This cross-sectional observational study was conducted, analyzing retrospective and current clinical data from patients who had undergone liver transplantation and were referred by a hepatologist for cardiologist consultation. The study included 74 subjects aged 61 (56-65) years (men, 60,8%). The period after liver transplantation was 2,8 (1,1-7,6) years. Cardiometabolic risk factors for atherosclerosis, laboratory and imaging data, and medications were analyzed. Results.  A high prevalence of following cardiometabolic risk factors was identified: atherogenic dyslipidemia (91,9%), hypertension (87,8%), carbohydrate metabolism disorders (58,1%), including type 2 diabetes (50,0%), and abdominal obesity (78,4%). Mixed hyperlipidemia was the predominant lipid metabolism disorder (48,6%), followed by pure hypercholesterolemia (31,1%) and pure hypertriglyceridemia (8,1%). Hypoalphacholesterolemia was detected in 4,1%. One in five patients with hyperlipidemia (21,5%) had severe hypercholesterolemia (low-density lipoprotein cholesterol >4,9 mmol/L). Despite the fact that 95,9% of patients had high or very high cardiovascular risk (CVR), only 9,5% received LLT associated with a reduction in CVR. Only 2 patients (2,7%) achieved target LDL cholesterol levels. Conclusion.  Liver transplant recipients referred to a cardiologist have a high prevalence of cardiometabolic risk factors, and the dyslipidemia pattern is characterized by a predominance of mixed hyperlipidemia. A discrepancy was identified between high CVR and the extremely low proportion of individuals taking pathogenetic hormonal therapy, necessitating an optimized interdisciplinary approach to the management of these patients.

16 June 2023 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
ENElizaveta Novokhatskaya
Elizaveta Novokhatskaya
IKI. V. Kuznetsova
I. V. Kuznetsova
TRT. A. Ryabinina
T. A. Ryabinina
GIG. R. Imametdinova
G. R. Imametdinova
Polymyalgia rheumatica is a systemic inflammatory disease that is rarely diagnosed in clinical practice due to the low awareness of physicians and the absence of specific diagnostic markers. The case report is of particular interest due to the absence of typical laboratory signs and the presence of concomitant diseases in the patient with similar clinical manifestations. Timely diagnosis and the appointment of adequate therapy made it possible to achieve clinical and laboratory remission without irreversible consequences for the patient’s health.

14 March 2026 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
ENElizaveta Novokhatskaya
Elizaveta Novokhatskaya
AEAlexandra Ershova
Alexandra Ershova
ODOxana M. Drapkina
Oxana M. Drapkina
The study aim was to provide an overview of current data on the mechanism of action, clinical efficacy, and safety of bempedoic acid (BA) as a lipid-lowering drug. The methodological approaches included a literature search of PubMed, Web of Science, and Scopus for studies published before December 19, 2025. The review included randomized controlled trials (RCTs) evaluating the efficacy and safety of BA compared to placebo in patients with hypercholesterolemia, including the Cholesterol Lowering via Bempedoic Acid, an ACL-Inhibiting Regimen (CLEAR) series of studies. Data from metaanalyses and other clinical trials were also considered. The obtained results demonstrate that BA is the first oral adenosine triphosphate citrate lyase inhibitor, which plays an important role in the treatment of hypercholesterolemia. Due to tissue-specific activation mechanism, BA can be used in patients with statin intolerance. RCT data have demonstrated that when added to maximum-tolerated doses of statins, BA provides an additional reduction in low-density lipoprotein cholesterol (LDL-C) by 15-23%. In monotherapy, in patients with statin intolerance, LDL-C reduction reaches 23-27%. The combination of BA and ezetimibe demonstrated a reduction in LDL-C by 38-45%, and with high doses of statins, BA, and ezetimibe, a reduction of 68%. BA therapy also helps reduce high-sensitivity C-reactive protein levels by 19-32%. Longterm BA use is associated with a 13% reduction in the risk of cardiovascular events compared to placebo, with a favorable safety profile. A subanalysis of the CLEAR studies showed that BA does not increase the incidence of type 2 diabetes. Thus, BA is an effective and safe lipid-lowering agent that reduces the risk of major cardiovascular events and can be used both as monotherapy and in combination with other lipid-lowering agents.

31 July 2026 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
AKA. A. Kucherov
A. A. Kucherov
AEAlexandra Ershova
Alexandra Ershova
ENElizaveta Novokhatskaya
Elizaveta Novokhatskaya
VSV. E. Syutkin
V. E. Syutkin
ODOxana M. Drapkina
Oxana M. Drapkina
Aim . To describe the design of the Efficacy and Safety of Pitavastatin and PCSK9 Inhibitors in Liver Transplant Patients (PINTL) study and the baseline clinical and laboratory characteristics of liver transplant recipients with dyslipidemia randomized to receive pitavastatin or a PCSK9 inhibitor (proprotein convertase subtilisin/kexin type 9). Material and methods . This open-label, randomized, prospective, single-center study (PINTL, NCT05537948) enrolled 59 liver transplant recipients randomized 1:1 to pitavastatin (n=30) or a PCSK9 inhibitor (alirocumab/evolocumab, n=29). The study included two following 6-month phases: monotherapy and add-on combination therapy in patients who had not achieved target low-density lipoprotein (LDL) cholesterol (C). Efficacy endpoints included absolute and percentage reductions in LDL-C, the proportion of target level achievement, and the timeframe for achieving and maintaining it. Safety endpoints included the incidence of adverse events, changes in liver enzymes, creatine phosphokinase, and immunosuppressant levels. Results . All patients in the pitavastatin group and 89,7% in the PCSK9 inhibitor group received tacrolimus; 60,0% and 55,2%, respectively, received tacrolimus in combination with everolimus. All patients had high or very high cardiovascular risk; the proportion of patients at very high risk was 33,3% and 20,7%, respectively (p=0,382). Before study inclusion, 20,0% and 13,8% of patients received lipid-lowering therapy, and 13,3% and 0% received statins, respectively. The groups did not differ in most baseline clinical and laboratory parameters. The γ-glutamyl transferase level was higher in the group receiving the PCSK9 inhibitor as follows: 46 (31-103) vs 30 (23-59) U/L (p=0,033). Conclusion . The study cohort had a high cardiovascular risk burden and a low frequency of lipid-lowering therapy prescription. Baseline comparability between the groups will make it possible to evaluate the efficacy and safety of the lipid-lowering strategies studied. The baseline difference in γ-glutamyl transferase levels will be taken into account in further analysis.